Drug Combination Details

General Information of the Combination (ID: C84024)
Name Aclarubicin + Cytarabine + GC-SF
    Click to Show/Hide the Each NP or Drug Information of This Combination
Name Aclarubicin   NP Info     Drug Info 
Structure
Name    Drug Info 
Structure
Disease
Acute myeloid leukemia [ICD-11: 2A60]
Phase 2 [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [2]
                    Experimental
                    Result(s)		 Increasing the dose of aclarubicin in CAG regimen seemed to be useful and relatively safe in relapsed and refractory AML.
References
Reference 1 ClinicalTrials.gov (NCT03045627) Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients.
Reference 2 Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia. Int J Hematol. 2014;99(5):603-8.
 Download Picture         KEGG Link